Interactions Leading News Today

Analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF ...

Results from VALOR-HCM LTE demonstrated that with longer follow-up, CAMZYOS continued to reduce eligibility for invasive SRT at 56 weeks EXPLORER-LTE data showed sustained improvements in LVOT...

New analyses, including late-breaking data and presentations on CAMZYOS® and Eliquis® , reaffirm the companys steadfast dedication to tackling cardiovascular diseases ...

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 26, 2023--

CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 15, 2023--

16.06.2023 - Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the Phase 3 VALOR-HCM study to the U.S. Prescribing Information for ...

If approved, CAMZYOS would be the first cardiac myosin inhibitor in Europe that specifically targets the source of obstructive HCM Recommendation based on positive Phase 3 EXPLORER-HCM and... | June 18, 2023

Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbr